Gamida Cell’s (NASDAQ: GMDA) share price has jumped 19% after the company announced data from its Phase 3 study of omidubicel.
The company said that the drug is an investigational advances cell therapy and could be used as a “potential life-saving treatment option for patients in need of bone marrow transplant.” The study met its primary endpoint as well as all three of its secondary endpoints.
Julian Adams, Ph.D., chief executive officer of Gamida Cell, stated that the additional data “reinforce the potential of omidubicel and move us another step closer toward bringing potentially curative therapies to patients.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Gamida said that they are continuing to work to enable the submission of its biologics license application for omidubicel to the FDA, which is expected in the fourth quarter.
Gamida Cell stock…
Gamida’s share price has jumped premarket on Tuesday since the news was announced. After closing Monday’s session at $4.20, shares are now priced at $4.80, up 14%.
PEOPLE WHO READ THIS ALSO VIEWED:
